Compare Amphastar Pharmaceuticals Inc (AMPH) vs Southern Copper Corp (SCCO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Southern Copper Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Southern Copper Corp trades at $174.85 (market cap $146.70B). The key difference: Southern Copper Corp is far larger — about 177.6× Amphastar Pharmaceuticals Inc's market cap, and Southern Copper Corp pays a 2.27% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | SCCO | |
|---|---|---|
Market Cap | $826.08M | $146.70B |
Sector | Health | Basic Materials |
52-Week High | $30.81 | $218.85 |
52-Week Low | $16.87 | $90.54 |
Enterprise Value | $1.22B | $148.75B |
Dividend Yield | — | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
SCCO trades at $175.83, up 0.8% on the day, with a neutral technical signal and bearish moving averages. The stock exhibits strong fundamentals, with revenue growing from $10.0B in 2022 to $13.4B in 2025 and net income margin expanding to 34.13%. Recent earnings beats and a $1.00 dividend payment in May 2026 highlight operational strength. However, valuation ratios like a P/E of 29.77 and P/B of 12.45 suggest premium pricing relative to historical norms.
The outlook for SCCO is mixed; robust earnings growth and positive analyst coverage from Zacks (Strong Buy on July 10, 2026) support upside potential, but high valuations and a consensus price target of $151.58 indicate near-term overvaluation risks. Key risks include commodity price volatility and execution challenges in capital expenditures, while institutional sentiment remains cautious with only 10.34% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
